Trial Profile

A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Atazanavir; Cobicistat; Darunavir
Indications HIV-1 infections
Focus Adverse reactions; Biomarker; Pharmacodynamics
Sponsors Gilead Sciences

Most Recent Events

23 Jul 2014 Planned End Date changed from 1 Jun 2014 to 1 Dec 2014 as reported by the ClinicalTrials.gov .
10 Jan 2014 Planned End Date changed from 1 Mar 2014 to 1 Jun 2014 as reported by the ClinicalTrials.gov record.
11 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com